Filing Details

Accession Number:
0000059478-16-000308
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-02-03 14:04:31
Reporting Period:
2016-02-01
Filing Date:
2016-02-03
Accepted Time:
2016-02-03 14:04:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
59478 Lilly Eli & Co LLY Pharmaceutical Preparations (2834) 350470950
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1538604 A David Ricks Lilly Corporate Center
Indianapolis IN 46285
Svp And Pres, Lilly Bio-Meds No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-02-01 9,843 $0.00 89,792 No 4 M Direct
Common Stock Disposition 2016-02-01 4,656 $79.10 85,136 No 4 F Direct
Common Stock Disposition 2016-02-01 3,273 $78.36 81,863 No 4 S Direct
Common Stock Disposition 2016-02-03 2,460 $76.73 79,403 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2016-02-01 9,843 $0.00 9,843 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-02-01 2016-02-01 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 4,222 Indirect 401(k)
Footnotes
  1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2015.
  2. This transaction was executed in multiple trades at prices ranging from $78.19 to $78.61. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $76.46 to $76.92. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.